- **Tvardi Therapeutics, Inc.** announced that its **Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its goals**, with preliminary data showing **no statistically significant differences in exploratory efficacy** between treatment arms and placebo.  **[1346830_0001104659-25-098908_tm2528638d1_ex99-1.htm:1]** 
- The trial experienced **high discontinuation rates** in the TTI-101 treated arms (**56.7% for 400mg and 62.1% for 800mg**) compared to placebo (**10.3%**), primarily due to gastrointestinal adverse events.  **[1346830_0001104659-25-098908_tm2528638d1_ex99-1.htm:1]** 
- Tvardi remains on track to report preliminary topline data in the **first half of 2026** for a healthy volunteer study of TTI-109 and a Phase 2 trial of TTI-101 in hepatocellular carcinoma.  **[1346830_0001104659-25-098908_tm2528638d1_ex99-1.htm:2]** 
- As of **June 30, 2025**, the company reported **$41.0 million in cash, cash equivalents, and short-term investments**, which is expected to fund operations into the **fourth quarter of 2026**.  **[1346830_0001104659-25-098908_tm2528638d1_ex99-1.htm:2]**

Tvardi Therapeutics (TVRD)